香菊胶囊联合枸地氯雷他定对慢性鼻窦炎患者黏膜组织重塑及炎症反应的影响

Effect of Xiangju capsule combined with desloratadine citrate on mucosal tissue remodeling and inflammatory response in patients with chronic sinusitis

目的:观察香菊胶囊联合枸地氯雷他定治疗慢性鼻窦炎(CS)患者的临床疗效及对黏膜组织重塑及炎症反应的影响。方法:选取本院2019年3月—2020年4月就诊的97例CS患者,依随机数字表法分为对照组(48例)和观察组(49例),两组均接受鼻腔冲洗、增强体质等常规对症治疗,并口服克拉霉素分散片0.25 g/次,2次/d。对照组在常规治疗基础上,给予枸地氯雷他定胶囊口服,8.8 mg/次,1次/d;观察组在对照组治疗基础上,加用香菊胶囊口服,0.6 g/次,3次/d。两组疗程均为3个月。比较两组临床疗效,两组治疗前后黏膜组织重塑情况[气道损伤情况、转化生长因子β1(TGF-β1)],检测并比较两组炎症指标[总免疫球蛋白E(TIgE)、白介素17(IL-17)、嗜酸性粒细胞阳离子蛋白(ECP)];记录两组患者疗程内不良反应发生情况。结果:观察组和对照组总有效率分别为93.88%和79.17%,差异有统计学意义(P<0.05)。两组气道损伤治疗前后比较均有改善,治疗后观察组气道损伤改善情况优于对照组;两组TGF-β1、TIgE、IL-17、ECP水平均低于治疗前(P<0.05),治疗后观察组TGF-β1、TIgE、IL-17、ECP水平均低于对照组,差异均有统计学意义(P<0.05);组间不良反应发生率比较差异无统计学意义(P>0.05)。结论:香菊胶囊联合枸地氯雷他定治疗CS疗效肯定,有利于抑制黏膜组织重塑,减轻炎症反应,安全性好。

Objective:To observe the overall benefit of Xiangju capsule combined with desloratadine citrate in the treatment of patients with chronic sinusitis(CS),and its influence on mucosal tissue remodeling an inflammatory response.Methods:According to the random number table,a total of 97 patients with CS in our hospital from March 2019 to April 2020 were selected and divided into group A(48 cases,desloratadine citrate treatment)and group B(49 cases,Xiangju capsule combined desloratadine citrate treatment).Both groups received routine symptomatic treatment such as nasal irrigation and strengthening system,and took clarithromycin dispersible tablets(0.25 g/time,twice a day).On the basis of conventional treatment,the control group was given oral desloratadine citrate capsule(8.8 mg/time,once a day),while the observation group was given Xiangju capsule(0.6 g/time,3 times a day)on the basis of treatment in control group.The course of treatment was 3 months in both groups.The clinical efficacy,mucosal tissue remodeling(airway injury,transforming growth factorβ1(TGF-β1))before and after treatment were compared between the two groups,and the inflammatory indexes(total immunoglobulin E(TIgE),interleukin 17(IL-17),eosinophil cationic protein(ECP))were detected and compared between the two groups.The occurrence of adverse reactions of patients within 3 months of treatment was recorded.Results:The total effective rates of the observation group and the control group was 93.88%and 79.17%,respectively,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in mucosal tissue remodeling and inflammatory index test results between the two groups(P>0.05).After treat ment,the improvement of airway injury in the observation group was better than that in the control group.The levels of TGF-β1,TIgE,IL-17,and ECP after treatment were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the groups(P>0.05).Conclusion:Xiangju capsule combined with desloratadine citrate has a positive effect in the treatment of CS,which is beneficial to inhibit mucosal tissue remodeling,reduce inflammation and has good safety.